Analyst Target Update on Nivalis Therapeutics Inc (NASDAQ:NVLS)

In the last session of trading, Nivalis Therapeutics Inc (NASDAQ:NVLS) shares changed +2.35%. Sell-side analysts covering the company are looking for the stock to go to $16.63 within the next 52 weeks. Target prices can vary greatly depending on the analyst providing projections. This target is the consensus price coming from analysts polled by Thomson Reuters. 

Wall Street analysts have the ability to use various metrics to help calculate target projections. A commonly used metric is a company’s P/E Ratio. This calculation stems from dividing the current share price by the projected earnings per share. At the time of this writing, Nivalis Therapeutics, Inc. has a price to earnings ratio of N/A. Investors may also evaluate a company’s PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may indicate that the company is overvalued. A PEG Ratio near one may be seen as fair value. The stock presently has a PEG Ratio of 0.00.

Taking a brief view of stock performance, we see that company shares are currently trading $0.33 off the 50-day moving average of $2.28 and $-2.33 off of the 200-day moving average of $4.94. The stock has been recently recorded -72.09% off of the 52-week high of 9.35 and +30.50% away from the 52-week low of 2.00. Tracking the stock price relative to moving averages and highs and lows for the year may help evaluate the future value of the stock.